Daiichi Sankyo sales and marketing update

The U.K.’s NICE issued draft guidance recommending Daiichi’s Lixiana edoxaban as an option to prevent stroke and systemic embolism in adults with non-valvular atrial fibrillation (AF) and one or more additional risk factors. The draft guidance recommends the oral factor Xa inhibitor as an alternative to warfarin in the same indication. ...